Supernus Pharmaceuticals
SUPN
#5345
Rank
A$2.33 B
Marketcap
A$40.06
Share price
5.89%
Change (1 day)
-42.66%
Change (1 year)

Earnings for Supernus Pharmaceuticals (SUPN)

Earnings in 2026 (TTM): -A$0.18 Billion

According to Supernus Pharmaceuticals 's latest financial reports the company's current earnings are A$0.83 Billion. In 2025 the company made an earning of -A$64.36 Million a decrease over its 2024 earnings that were of A$0.11 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Supernus Pharmaceuticals from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -A$0.18 Billion175.43%
2025 -A$64.36 Million-155.5%
2024 A$0.11 B1446.62%
2023 A$7.49 M-92.36%
2022 A$98.07 M-29.8%
2021 A$0.13 B-49.79%
2020 A$0.27 B12.99%
2019 A$0.24 B7.58%
2018 A$0.22 B54.9%
2017 A$0.14 B84.25%
2016 A$80.2 M202.27%
2015 A$26.53 M-462.04%
2014 -A$7.33 Million-94%
2013 -A$0.13 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
A$27.07 B-15,720.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
A$11.76 B-6,889.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$50.28 B-29,110.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$16.38 B-9,555.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Zogenix
ZGNX
-A$0.31 Billion 76.92%๐Ÿ‡บ๐Ÿ‡ธ USA
United Therapeutics
UTHR
A$2.29 B-1,422.50%๐Ÿ‡บ๐Ÿ‡ธ USA